Trial reportPharmacoEconomics2000
Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group.
Trial report in PharmacoEconomics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2009Pooled it
- Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents.Clinical drug investigation · 2006Pooled it
- [Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment].Wiener medizinische Wochenschrift (1946) · 2010Trial
- Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.Human vaccines & immunotherapeutics · 2022Article
- A population-based estimate of the economic burden of influenza in Peru, 2009-2010.Influenza and other respiratory viruses · 2016Article
- The impact of influenza on working days lost: a review of the literature.PharmacoEconomics · 2008Review
- Pharmacoeconomics of antiviral therapy for influenza in a Japanese hospital setting.Clinical drug investigation · 2005Article
- Antiviral agents for influenza: a comparison of cost-effectiveness data.PharmacoEconomics · 2005Review
- Health-related quality of life of adults with upper respiratory tract infections.Journal of general internal medicine · 2003Article
- Economic evaluations of neuraminidase inhibitors to control influenza.Expert review of pharmacoeconomics & outcomes research · 2003Article
- Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.PharmacoEconomics · 2003Article
- Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis.PharmacoEconomics · 2003Article
- Zanamivir: an update of its use in influenza.Drugs · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study examined the impact of zanamivir treatment on patient morbidity in patients with influenza. DESIGN AND
settingThis was a multicentre, randomised, double-blind, parallel-group study conducted in 14 countries in Europe and North America during the winter of 1995/1996. PATIENTS AND
participantsThe study included 722 individuals with virologically confirmed influenza.
interventionsTwo different zanamivir treatment regimens [twice daily (bid) or 4 times daily (qid) for 5 days] were compared with placebo. MAIN OUTCOME MEASURES AND
resultsEfficacy was measured using a number of patient-assessment questionnaires. Results showed that significantly fewer patients with influenza who were treated with zanamivir had additional contacts with healthcare professionals compared with those who received placebo (8 vs 14%; p < or = 0.049, bid and qid vs placebo). Individuals treated with zanamivir also spent fewer days absent from work (placebo: mean = 3.28 days; qid: mean = 2.52 days; p = 0.031) or college/school (placebo: mean = 2.90 days; bid: mean = 2.24 days; p = 0.032), and showed significant improvements in productivity compared with placebo. The health status questionnaire revealed significant improvements in patient well-being over the first 5 days of the study in those treated with zanamivir compared with those who received placebo.
conclusionsZanamivir treatment reduced absenteeism, improved patient productivity and well-being, and reduced the additional use of healthcare resources in patients with influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.